[Value of experimental and clinical methods on the effectiveness and side effect profile of anti-arrhythmia agents].
The suppression by antiarrhythmic drugs of ventricular premature beats, pairs and salvos is frequently not associated with a suppression of ventricular tachycardia or fibrillation in the same patient. The evaluation of antiarrhythmic drugs must therefore distinguish between antiectopic, anti-reentry and anti-fibrillatory efficacy. Clinical methods such as Holter monitoring and programmed electrical stimulation which only allow the validation of anti-ectopic or anti-reentry efficacy present a major problem in the evaluation of antiarrhythmic drugs. Anti-fibrillatory drug efficacy cannot be evaluated by clinical methods.
Kuck
K H
KH
Abt. Kardiologie, Universitätskrankenhaus Eppendorf.
D000889:Anti-Arrhythmia Agents / Q000009:adverse effects / Q000627:therapeutic use*; D005117:Cardiac Complexes, Premature / Q000139:chemically induced / Q000188:drug therapy / Q000401:mortality; D002304:Cardiac Pacing, Artificial; D015716:Electrocardiography, Ambulatory / Q000187:drug effects; D006801:Humans; D015996:Survival Rate; D013610:Tachycardia / Q000139:chemically induced / Q000188:drug therapy* / Q000401:mortality; D014693:Ventricular Fibrillation / Q000139:chemically induced / Q000188:drug therapy / Q000401:mortality
D000889:Anti-Arrhythmia Agents
Aussagewert von experimentellen und klinischen Methoden zur Wirksamkeit und zum Nebenwirkungsprofil von Antiarrhythmika.